Podiatrists in Augusta, ME Accepting Medicare
7 Podiatrists found. Showing 1 - 7
 Dr. Michael David Kipp, D.P.M. Podiatrist Medicare: May Accept Medicare Assignments Practice Location: 3 Saint Catherine St, Augusta, ME 04330 Phone: 207-620-7273 Fax: 207-620-7275 |
Dr. Daniel James Benson, DPM Podiatrist - Foot Surgery Medicare: Accepting Medicare Assignments Practice Location: 12 Spruce St, Suite #5, Augusta, ME 04330 Phone: 207-626-0100 Fax: 207-626-0800 |
 Foot And Ankle Of Augusta Pa Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 3 Saint Catherine St, Augusta, ME 04330 Phone: 207-620-7273 Fax: 207-620-7275 |
Dr. Andrew Taylor Smith Iii, D.P.M Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 26 Eastern Ave, Augusta, ME 04330 Phone: 207-623-5100 Fax: 207-621-1822 |
Alan L. Lipman, D.P.M. Podiatrist - Primary Podiatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 2 Hillcrest St, Augusta, ME 04330 Phone: 207-623-3069 |
 Dr. Melissa Williams, D.P.M. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 1 Va Center, Augusta, ME 04330 Phone: 207-623-8411 |
Dr. Andrew T. Smith, Dpm, Dba Augusta Foot And Ankle Center Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 26 Eastern Ave, Augusta, ME 04330 Phone: 207-623-5100 Fax: 208-621-1822 |
News Archive
Researchers propose new avenue in the search for anti-obesity drugs
Effective weight-loss strategies call for eating less food, burning more calories-or ideally, both. But for the more than 90 million Americans who suffer from obesity, a disease that contributes to conditions ranging from cancer to heart disease, behavioral change is hard to accomplish or not effective enough-which is why scientists have long sought drugs that would help people shed pounds.
Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates
Although a variety of nanoparticles continue to show promise for improving cancer imaging and therapy, regulators and drug developers are concerned that these delivery systems may prove difficult to manufacture on a consistent basis, which is key for any agent designed for use in humans.
Dolutegravir-based regimen demonstrates superiority over Atripla in treatment-naive adults with HIV-1
Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the investigational integrase inhibitor dolutegravir in treatment-naive adults with HIV-1.
Australian alliance to commercialise new genetic tests for epilepsy
Bionomics Limited and Genetic Technologies Limited have formed a strategic alliance to commercialise new genetic tests for epilepsy. These new diagnostic tools will enable earlier diagnosis, more precise treatment and better overall outcomes for those suffering from inherited forms of epilepsy.
› Verified 7 days ago
Occupational Therapists
Physical Therapists
Speech-Language Pathologists
Chiropractors
Optometrists
Audiologists
Podiatrists